Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
Clinical trial NCT06504901 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06504901
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-07-10
- Primary completion
- 2025-07-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.